(CercleFinance.com) – AstraZeneca announced on Friday that it has launched legal action in the United States to protect access to drugs against cancer and rare diseases, which it considers threatened by the provisions of the Inflation Reduction Act’ (IRA).
The pharmaceutical company explains that the current version of the law risks delaying the commercialization of treatments intended for American patients suffering from rare diseases, who have benefited so far according to him from the ‘Orphan Drug Act’, a text of law favoring the development of orphan drugs.
AstraZeneca argues that many cancer drugs are first launched in an orphan indication, before their use is expanded to other indications over time, as has been the case with its Lynparza for ovarian cancer. .
‘If the IRA had been implemented, significant deterrents would have existed, resulting in late approval in ovarian cancer in the United States’, justifies the group.
The IRA provides for reform of prescription drug pricing, which includes the provision that the US government will be able to determine the price of certain treatments from 2026.
Listed on the London Stock Exchange, AstraZeneca shares fell 0.4% on Friday afternoon following these announcements.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
